Your search for Warfarin returned 43 results

For patients with nonvalvular atrial fibrillation (NVAF), left atrial appendage closure (LAAC) is associated with reduced rates of hemorrhagic stroke, cardiovascular/unexplained death, and nonprocedural bleeding vs. warfarin.

For patients with atrial fibrillation hospitalized with stroke or transient ischemic attack, use of novel oral anticoagulants (NOACs) has increased over time.

For patients with atrial fibrillation, decline in renal function is significantly greater with warfarin vs. dabigatran etexilate (DE), according to a study published in the Journal of the American College of Cardiology.

For patients with diabetes mellitus undergoing multivessel coronary artery bypass grafting (CABG), predictors of stroke include previous stroke, warfarin use, and surgery outside the United States or Canada.

Obese patients taking warfarin have a higher risk of experiencing a bleeding event compared to their normal-weight counterparts, a new study suggests.

The presence of one additional stroke risk factor is associated with a significant increase in event rates among untreated low-risk patients with nonvalvular atrial fibrillation (CHA2DS2-VASc = 0 [male], 1 [female]).

For patients with atrial fibrillation receiving anticoagulant treatment, the presence of anemia is associated with increased risk of thromboembolic events, bleeding complications, and mortality.

Direct oral anticoagulants (DOACs) have distinct bleeding profiles and require individualized management approaches, according to a new review.

Because of various clinical situations, there may be a need for clinicians to transition patients from one anticoagulant therapy to another. In order to do this safely, the pharmacology profiles of both agents should be taken into consideration.

Overtreatment with anticoagulation for atrial fibrillation may double risk for dementia.